

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Rilpivirine

March 17, 2026

Therapeutic category

Anti-virus agents

Non-proprietary name

Rilpivirine

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision							
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin, fosphenytoin, dexamethasone (systemic administration) (excluding single administration), or food containing St. John's Wort</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p>(N/A)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin, fosphenytoin, <u>apalutamide</u>, <u>enzalutamide</u>, dexamethasone (systemic administration) (excluding single administration), or food containing St. John's Wort</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="1131 826 1982 1214"> <thead> <tr> <th data-bbox="1131 826 1473 922">Drugs</th> <th data-bbox="1476 826 1758 922">Signs, symptoms, and treatment</th> <th data-bbox="1760 826 1982 922">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1131 924 1473 1214"> <u>Apalutamide</u> <u>Enzalutamide</u> </td> <td data-bbox="1476 924 1758 1214"> <u>The blood concentration of rilpivirine may decrease, leading to attenuation of the effects of rilpivirine.</u> </td> <td data-bbox="1760 924 1982 1214"> <u>The CYP3A-inducing activity of these drugs promotes the metabolism of rilpivirine.</u> </td> </tr> </tbody> </table>		Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Apalutamide</u> <u>Enzalutamide</u>	<u>The blood concentration of rilpivirine may decrease, leading to attenuation of the effects of rilpivirine.</u>	<u>The CYP3A-inducing activity of these drugs promotes the metabolism of rilpivirine.</u>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors						
<u>Apalutamide</u> <u>Enzalutamide</u>	<u>The blood concentration of rilpivirine may decrease, leading to attenuation of the effects of rilpivirine.</u>	<u>The CYP3A-inducing activity of these drugs promotes the metabolism of rilpivirine.</u>						

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.